TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, INCREASES INSULIN SENSITIVITY AND IMPROVES PANCREATIC BETA-CELL FUNCTION IN TYPE 2 DIABETES

被引：0
|
作者：
Pirro, V. [1 ]
Nikooienejad, A. [1 ]
Lin, Y. [1 ]
Willency, J. [1 ]
Wilson, J. [1 ]
Duffin, K. [1 ]
Robins, D. [1 ]
Milicevic, Z. [1 ]
Haupt, A. [1 ]
Thomas, M. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P232 / #49
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [31] Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
    Dahl, Dominik
    Onishi, Yukiko
    Norwood, Paul
    Huh, Ruth
    Patel, Hiren
    Rodriguez, Angel
    DIABETES, 2021, 70
  • [32] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [33] GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia
    Redondo, Maria J.
    Bacha, Fida
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (08): : E3000 - E3002
  • [34] Tirzepatide, a dual GIP/GLP-1 receptor agonist, interrupts metabolic adaptation to dietary restriction
    Coskun, T.
    Roell, W. C.
    O'Farrell, L. S.
    Beebe, E. C.
    Regmi, A.
    Emmerson, P. J.
    Milicevic, Z.
    Haupt, A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S58 - S59
  • [35] Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes
    Nauck, M. A.
    Frias, J. P.
    Van, J.
    Benson, C. T.
    Bray, R.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    DIABETOLOGIA, 2019, 62 : S59 - S59
  • [36] Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
    Ma, Zijun
    Jin, Kaiqin
    Yue, Mengmeng
    Chen, Xin
    Chen, Jun
    JOURNAL OF DIABETES RESEARCH, 2023, 2023
  • [37] Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
    Rangraze, Imran Rashid
    Khan, Shehla
    Wali, Adil Farooq
    Menezes, Godfred
    Goud, Manjunatha
    Jabran, Muhammad
    CURRENT DRUG SAFETY, 2024,
  • [38] Indices of beta-cell function: association with diabetes control in patients with type 2 diabetes on stable GLP-1 agonist treatment
    Behary, Preeshila
    Godsland, Ian F.
    Baynes, Kevin C.
    PRACTICAL DIABETES, 2014, 31 (05) : 202 - 205
  • [39] Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes
    Rosenstock, Julio
    Robins, Deborah A.
    Duffin, Kevin L.
    Wilson, Jonathan M.
    Mather, Kieren J.
    Banerjee, Hiya
    Lin, Yanzhu
    Eyde, Sarah
    Kazda, Christof M.
    Konig, Manige
    DIABETES, 2024, 73
  • [40] Effects of tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, on biomarkers of non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes
    Haupt, A.
    Sanyal, A.
    Loomba, R.
    Wilson, J.
    Bray, R.
    Nikooienejad, A.
    Duffin, K.
    Robins, D.
    Hartman, M.
    DIABETOLOGIA, 2019, 62 : S91 - S91
12345